{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-037633","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.100280+00:00","generated_at":"2026-06-21T21:35:09.035004+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TherapeuticsMD Q3 revenue $20.9M, net loss $29.0M; cash drops to $27.1M","bullets":["Net revenue $20.9M, down 18% YoY; net loss $29.0M ($3.13/sh) vs $47.4M loss YoY.","Operating expenses cut $22.2M YoY to $37.9M; product gross margin 82% vs 78%.","ANNOVERA revenue $10.4M (-$1.4M YoY), Rx up 10% YoY; IMVEXXY $6.9M; BIJUVA $2.7M.","Cash $27.1M at Sep 30, down from $65.1M at Dec 31; post-quarter $7M investment from Rubric Capital.","Net debt and preferred stock liability $117.1M; no earnings call due to strategic alternatives review."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-037633","json":"https://secwatch.observer/filing/0001564590-22-037633.json","markdown":"https://secwatch.observer/filing/0001564590-22-037633.md","text":"https://secwatch.observer/filing/0001564590-22-037633.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000156459022037633/0001564590-22-037633-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000156459022037633/txmd-8k_20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:35:09.035004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33a0f0545822dc274fd5caffb34e2e06c250422b","claim":"TherapeuticsMD, Inc. reported the third quarter ended September 30, 2022 results: revenue $20.9 million, net income $29.0 million, EPS $3.13 per basic and diluted share.","evidence_excerpt":"Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/25743/000156459022037633/0001564590-22-037633-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$20.9 million"},{"label":"Net income","value":"$29.0 million"},{"label":"EPS","value":"$3.13 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}